Fagron realises turnover of € 103.4 million
12 Outubro 2016 - 2:00AM
Regulated information
Waregem (Belgium) / Rotterdam (The Netherlands), 12 October
2016
Fagron realises
turnover of € 103.4 million
Developments new facility in Wichita in line with
expectations
During the third quarter of 2016, Fagron Group
realised a consolidated turnover from continued operations of
€ 103.4 million, a decrease of 1.1% (-2.7% at constant
exchange rates) compared to the third quarter of 2015. In the first
nine months of 2016, the consolidated turnover from continued
operations decreased by 2.5% (+0.6% at constant exchange rates) to
€ 313.6 million. Organic turnover from continued operations
showed a decline of 5.2% (-2.2% at constant exchange rates).
Turnover (x € 1,000) |
Q3 2016 |
Q3 2015 |
Total
growth |
Total
growth
CER |
Org.
growth |
Org.
growth
CER |
Fagron |
101,862 |
102,719 |
-0.8% |
-2.5% |
-0.8% |
-2.5% |
HL
Technology |
1,538 |
1,818 |
-15.4% |
-14.7% |
-15.4% |
-14.7% |
Fagron Group (continued operations) |
103,401 |
104,537 |
-1.1% |
-2.7% |
-1.1% |
-2.7% |
Discontinued operations |
-1 |
9,001 |
-100% |
-99.9% |
-100% |
-99.9% |
Total |
103,400 |
113,538 |
-8.9% |
-10.4% |
-8.9% |
-10.4% |
Turnover (x € 1,000) |
9M 2016 |
9M 2015 |
Total
growth |
Total
growth
CER |
Org.
growth |
Org.
growth
CER |
Fagron |
307,540 |
314,216 |
-2.1% |
1.0% |
-4.9% |
-1.9% |
HL
Technology |
6,097 |
7,317 |
-16.7% |
-14.2% |
-16.7% |
-14.2% |
Fagron Group (continued operations) |
313,637 |
321,534 |
-2.5% |
0.6% |
-5.2% |
-2.2% |
Discontinued operations |
4,158 |
35,772 |
-88.4% |
-88.4% |
-88.4% |
-88.4% |
Total |
317,795 |
357,305 |
-11.1% |
-8.3% |
-13.3% |
-10.6% |
CER = constant exchange rates
Hans Stols, CEO Fagron: "The sterile
activities of Fagron Specialty Pharma Services (FSPS) in the United
States and the activities in South America and Rest of World have
developed positively in the last quarter. Turnover in Europe
remained below the level of the unusually strong third quarter of
2015.
In the US, turnover of Fagron
Essentials and Fagron Trademarks have been negatively impacted as a
result of both the changed reimbursement system and the
initiated process to integrate Freedom Pharmaceuticals and Fagron
Inc., to be centralised in Minneapolis.
In the period under review we
have made good progress with the expansion of the FSPS sales team
in the United States, which is now practically fully deployable.
Validation of the products for the new Wichita facility is
proceeding as planned. It is expected that the facility will have
received all required licences and will have completed the
validation processes early 2017.
Recently the Board of Directors
has initiated the process to explore strategic options for HL
Technology. After completion of their findings, we will inform the
market."
Please open the link below for the press
release:
Fagron realises turnover of € 103.4
million
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Fagron NV via Globenewswire
Wt Agricultu Ld (LSE:FAGR)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Wt Agricultu Ld (LSE:FAGR)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
Notícias em tempo-real sobre Wt Agricultu Ld da Bolsa de Valores de Londres bolsa de valores: 0 artigos recentes
Mais Notícias de Fagron NV